drugset
drugset / Trial / NCT06919081

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081 ↗

Phase 2 Recruiting 24 enrolled University of Illinois at Chicago National Eye Institute (NEI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Timeline

Start
2025-08-01
Primary completion
2026-03-15
Completion
2026-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome Unknown — Topical

Indications

corneal disorder